Exicure, Inc. (XCUR) — Stock Valuation & Research

Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.

XCUR key statistics

Price$1.03
Market cap$6.74M
SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
52-week range0.875-9.48
Beta3.64

Explore XCUR's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.